Peter Stephens

802 total citations
20 papers, 315 citations indexed

About

Peter Stephens is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Stephens has authored 20 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Stephens's work include PARP inhibition in cancer therapy (9 papers), Advanced Breast Cancer Therapies (5 papers) and DNA Repair Mechanisms (4 papers). Peter Stephens is often cited by papers focused on PARP inhibition in cancer therapy (9 papers), Advanced Breast Cancer Therapies (5 papers) and DNA Repair Mechanisms (4 papers). Peter Stephens collaborates with scholars based in United Kingdom, United States and France. Peter Stephens's co-authors include Nicola J. Curtin, Fiona K. Middleton, Tao Chen, Ruth Plummer, Debashis Sarker, Nicola Cresti, Yvette Drew, Nancy Hall, Bipin Mistry and Vaishali Dixit and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Peter Stephens

19 papers receiving 304 citations

Peers

Countries citing papers authored by Peter Stephens

Since Specialization

Citations

This map shows the geographic impact of Peter Stephens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Stephens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Stephens more than expected).

Fields of papers citing papers by Peter Stephens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Stephens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Stephens. The network helps show where Peter Stephens may publish in the future.

Co-authorship network of co-authors of Peter Stephens

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Stephens. A scholar is included among the top collaborators of Peter Stephens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Stephens. Peter Stephens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010). 2022 ·Journal of Clinical Oncology ·Alistair Ring, Laura Moretti, (unknown), Andrew Wardley, Lucy Kilburn, Bora Gürel, Iain R. Macpherson, Richard D. Baird, Sue Martin, Alex Pearson, Rebecca Roylance, Matthew Winter, (unknown), Ellen Copson, Tamas Hickish, Peter Stephens, Russell Burcombe, (unknown), Judith M. Bliss, Nicholas C. Turner	1
2	Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC). 2021 ·Journal of Clinical Oncology ·Amit Bahl, Jeremy Braybrooke, Alicia Bravo, Emily Foulstone, (unknown), Mark Churn, (unknown), (unknown), Rebecca Bowen, Simon Waters, Pippa Riddle, Duncan Wheatley, Peter Stephens, Janine Mansi, Pavel Bezecny, Srinivasan Madhusudan, Mark Verrill, (unknown), S.K. Pearson, William Wilson	2
3	First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor 2020 ·British Journal of Cancer ·Ruth Plummer, (unknown), Nicola Cresti, Yvette Drew, Peter Stephens, Marie L. Foegh, Steen Knudsen, Perminder S. Sachdev, Bipin Mistry, Vaishali Dixit, Sharon McGonigle, Nancy Hall, Mark Matijevic, (unknown), Debashis Sarker	57
4	Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010) 2020 ·Cancer Research ·Iain R. Macpherson, Lucy Kilburn, Sarah Kernaghan, Andrew Wardley, Richard D. Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew Winter, Belinda Kingston, Katie Wilkinson, Alistair Ring, Judith M. Bliss, Nicholas C. Turner, (unknown)	1
5	Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010) 2020 ·Cancer Research ·Andrew Wardley, Lucy Kilburn, Sarah Kernaghan, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew Winter, Belinda Kingston, Katie Wilkinson, Judith M. Bliss, Alistair Ring, Nicholas C. Turner, (unknown)	2
6	First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker. 2018 ·Journal of Clinical Oncology ·Elizabeth Ruth Plummer, (unknown), Nicola Cresti, Aneta Suder, Yvette Drew, Peter Stephens, Marie L. Foegh, Steen Knudsen, Sharon McGonigle, Barbara Ink, Debashis Sarker	7
7	Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types 2017 ·Annals of Oncology ·Sadakatsu Ikeda, Laurie M. Gay, Dean C. Pavlick, Jon Chung, (unknown), (unknown), Julia A. Elvin, Eric A. Severson, Trever G. Bivona, Karen L. Reckamp, Samuel J. Klempner, S.-H.I. Ou, Alexa B. Schrock, V.A. Miller, Peter Stephens, Jeffrey A. Ross, Shridar Ganesan, Christine M. Lovly, Aaron S. Mansfield, (unknown)	3
8	Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal 2017 ·PharmacoEconomics ·Irina A. Tikhonova, Tracey Jones-Hughes, (unknown), Fiona C Warren, Sophie Robinson, Peter Stephens, Martin Hoyle	4
9	Topography of Tumor Mutational Burden (TMB) and Immune-related Genomic Alterations (GA) Across Gastrointestinal Malignancies (GIm): A Study of 22,570 Cases 2017 ·Annals of Oncology ·Samuel J. Klempner, Garrett M. Frampton, Joseph Chao, Michael Bailey, Peter Stephens, Jeffrey S. Ross, V.A. Miller, Shakir Ali, Alexa B. Schrock	2
10	BRAF genomic alterations in breast cancer 2016 ·Annals of Oncology ·Joan Albanell, (unknown), James Suh, (unknown), (unknown), VG Kaklamani, Sonia Ali, Virginia L. Miller, Peter Stephens, Laurie M. Gay, Jeffrey S. Ross	3
11	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio‐resistance in breast cancer 2015 ·Molecular Oncology ·Nouf H. Alsubhi, Fiona K. Middleton, Tarek M.A. Abdel-Fatah, Peter Stephens, Rachel Doherty, Arvind Arora, Paul M. Moseley, Stephen Chan, Mohammed A. Aleskandarany, Andrew R. Green, Emad A. Rakha, Ian O. Ellis, Stewart G. Martin, Nicola J. Curtin, Srinivasan Madhusudan	30
12	mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition 2015 ·Molecular Oncology ·Andrew J. Massey, Peter Stephens, (unknown), (unknown), Ruth Plummer, Nicola J. Curtin	18
13	3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer 2015 ·European Journal of Cancer ·(unknown), (unknown), (unknown), James Suh, Andreas Heilmann, Doron Lipson, Roman Yelensky, Juliann Chmielecki, Julia A. Elvin, Kartik Konduri, (unknown), Peter Stephens, Jeff Ross, (unknown)	3
14	Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Ruth Plummer, Peter Stephens, (unknown), (unknown), (unknown), Peter de Nully Brown, Mario Campone	24
15	Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales 2014 ·British Journal of Cancer ·Charlotte Chamberlain, Simon M. Collin, Peter Stephens, J L Donovan, Amit Bahl, William Hollingworth	18
16	Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma. 2014 ·Journal of Clinical Oncology ·Ruth Plummer, (unknown), Nicola Cresti, Aneta Suder, Yvette Drew, (unknown), Peter Stephens, (unknown), Begoña de las Heras, Barbara Ink, (unknown), Mark Matijevic, (unknown), Debashis Sarker	4
17	Phase 1 Study of the Parp Inhibitor E7449 As a Single Agent in Patients with Advanced Solid Tumors or B-Cell Lymphoma 2014 ·Annals of Oncology ·Ruth Plummer, (unknown), Nicola Cresti, Aneta Suder, Yvette Drew, (unknown), Peter Stephens, (unknown), (unknown), Barbara Ink, (unknown), (unknown), Sean McGrath, Debashis Sarker	2
18	Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single‑agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595). 2012 ·Journal of Clinical Oncology ·Mario Campone, Ruth Plummer, Peter Stephens, (unknown), (unknown), (unknown), (unknown), (unknown), Peter de Nully Brown, L. Kayitalire	6
19	Targeting the S and G2 checkpoint to treat cancer 2011 ·Drug Discovery Today ·Tao Chen, Peter Stephens, Fiona K. Middleton, Nicola J. Curtin	127
20	A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity. 2011 ·Journal of Clinical Oncology ·Richard D. Baird, B. Venugopal, (unknown), (unknown), Montserrat Blanco-Codesido, Edward J. Saunders, (unknown), D. Crawford, Peter Stephens, Deidre Wilkins, (unknown), Ann Forslund, Johan W. Smit, (unknown), Nele Fourneau, Peter Hellemans, Johann S. de Bono, Ruth Plummer, Udai Banerji, T. R. J. Evans	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact